|
CKC (blinded)
|
49
|
0
|
|
CKC (blinded)
|
156
|
0
|
|
RT (blinded)
|
0
|
136
|
|
Age [y], median (range)
|
57 (27–86)
|
58 (20–84)
|
|
DOTATOC PET RT-planning
|
6 (2.9%)
|
6 (4.4%)
|
|
Total dose [Gy], median (range)
|
25 (5–61)
|
59.4 (32.4–63)
|
|
Class algorithm: Low risk group, n (%)
|
6 (3%)
|
2 (1.5%)
|
|
Class algorithm Intermediate risk group, n (%)
|
12 (5.9%)
|
10 (7.4%)
|
|
Class algorithm High risk group, n (%)
|
184 (91.1%)
|
124 (91.2%)
|
|
Median follow-up
|
32.5 (2–135)
|
41.5 (1–232)
|
|
Definitive radiotherapy at first diagnosis
|
135 (65.9%)
|
57 (41.9%)
|
|
Adjuvant radiotherapy at first diagnosis
|
16 (7.8%)
|
34 (25%)
|
|
Definitive radiotherapy at relapse
|
54 (26.3%)
|
45 (33.1%)
|
|
No surgery
|
135 (65.9%)
|
52 (38.2%)
|
|
Biopsy
|
6 (2.9%)
|
5 (3.7%)
|
|
Subtotal resection
|
37 (18.0%)
|
52 (38.2%)
|
|
Gross total resection
|
25 (12.2%)
|
18 (13.2%)
|
|
Resectional status unclear
|
2 (1.0%)
|
9 (6.6%)
|
|
Previous RT
|
4 (2.0%)
|
1 (0.7%)
|
